Cancer Research and Treatment

A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy: Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park; Cancer Res Treat. 2014;46(1):19-26. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.19

PURPOSE
This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
MATERIALS AND METHODS
This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
RESULTS
Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
CONCLUSION
In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.

Citations

Citations to this article as recorded by

Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital
Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj
Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129. CrossRef
Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study
Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin
Journal of Pain and Symptom Management.2021; 62(3): e85. CrossRef
A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker
Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud
International Journal of Analytical Chemistry.2021; 2021: 1. CrossRef
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report
Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii
YAKUGAKU ZASSHI.2019; 139(4): 647. CrossRef
Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang
Oncotarget.2017; 8(63): 106249. CrossRef
Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies
Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang
Journal of Pain and Symptom Management.2016; 51(2): 278. CrossRef
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela
Journal of Global Oncology.2016; 2(3): 145. CrossRef
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K. Jordan, F. Jahn, M. Aapro
Annals of Oncology.2015; 26(6): 1081. CrossRef

11,946 View
66 Download
8 Web of Science
9 Crossref

Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures: Jung Ho Yoon, Min Soo Kim, Eun Hee Kook, Se Han Ahn, Se Young Jeong, Min Sung Han, Jung Kwon Huh, Hye Jin Kang, Im Il Na, Soo Youn Cho, Sang Bum Kim, Baek Yeol Ryoo, Sung Hyun Yang; Cancer Res Treat. 2008;40(3):145-150. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.145

Abstract PDF PubReader ePub

Primary gastric choriocarcinoma (PGC) is a rare tumor, and its pathogenesis is still uncertain. Most PGCs have been reported to possess an adenocarcinoma component of variable extent, and pure PGC is especially rare. The diagnosis of PGC is confirmed by exhibition of choriocarcinomatous components on biopsy and exhibition of β-hCG positive cell on immunohistochemical stain and elevation of the serum β-hCG. Moreover it must be confirmed that no other site including gonads displays any tumor masses. The PGC tends to be more invasive and to have early metastasis. The median survival is known to be less than several months. We report two cases. The first case was a 62 year-old man who was diagnosed as advanced gastric cancer (AGC) by endoscopic biopsy with hepatic metasasis and received palliative chemotherapy with modified FOLFOX regimen and Genexol plus cisplatin regimen. He underwent subtotal gastrectomy due to perforation of the stomach during chemotherapy. On post-operative biopsy, He was re-diagnosed as PGC and received another palliative chemotherapy modified FOLFIRI, BEP, EMACO, VIP. However, multiple liver metastases were aggravated, and also serum AFP level increased. Ultimately, the paient died 10 months after initial diagnosis. Another case was a 45 year-old man. On endoscopic biopsy, he was diagnosed as AGC of adenocarcinoma. On Chest and Abdomen CT, multiple pulmonary and hepatic metastasis were also confirmed. On liver biopsy, He was diagnosed as PGC. The immunohistochemical stains were performed and the results were cytokeratin positive, EMA negative and β-hCG weak positive. The serum β-hCG level was highly elevated. BEP, VIP and EMA/CO combination therapy were administered, but he died at 12th months after the initial diagnosis.

Citations

Citations to this article as recorded by

Morphological and molecular pathological features of the breast carcinoma with choriocarcinomatous features: A case report and a literature review
Jingchun Xu, Yi Xu, Cheng Xu, Cong Wang
Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: a rare primary gastric choriocarcinoma revealed on 18F-FDG PET/CT
Yi Zhao, Wei Diao, Suping Li, Mengxi Yang, Zhuzhong Cheng
Frontiers in Oncology.2023;[Epub] CrossRef
Severe thyrotoxicosis as initial presentation of gastric choriocarcinoma: a case report
Nicole M. Iñiguez-Ariza, Dalia Cuenca, Juvenal Franco-Granillo, Alberto Villalobos-Prieto, Janet Pineda-Díaz, Javier Baquera-Heredia
Journal of Medical Case Reports.2022;[Epub] CrossRef
Primary gastric choriocarcinoma: A case report
Zhang Xusheng, Yan Yuke, Meng Yun, Guo Huijun, Peng Jiangshan, Du Xueqin, Yang Xiaojun
Frontiers in Surgery.2022;[Epub] CrossRef
Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
Jina Yun, Sang W Lee, Sung H Lim, Se H Kim, Chan K Kim, Seong K Park
World Journal of Clinical Cases.2020; 8(21): 5334. CrossRef
Primary Gastric Choriocarcinoma Coexisting with Adenocarcinoma
Joo Hyun Lee, Jeong Kyun Lee, Dong Baek Kang
The Korean Journal of Gastroenterology.2019; 73(6): 350. CrossRef
Primary gastric choriocarcinoma with multiple metastases – A case report and literature review of carcinogenesis
Yiqin Xiong, Michelle X. Yang
Human Pathology: Case Reports.2019; 18: 200330. CrossRef
Collision tumor of choriocarcinoma and small cell carcinoma of the stomach: A case report
Shuichi Fukuda, Yoshinori Fujiwara, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Hajime Ishikawa, Masanori Tsujie, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
International Journal of Surgery Case Reports.2017; 37: 216. CrossRef
Primary Choriocarcinoma of the Stomach. A Case Report and Review of the Literature
Rahul Raghavapuram, Fadl H Veerankutty, M Anandakumar
Indian Journal of Surgical Oncology.2016; 7(1): 119. CrossRef
A Case of a Duodenal Papilla Adenosquamous Carcinoma with Trophoblastic Differentiation
Daichi KITAGUCHI, Shingo SAKASHITA, Shinji HASHIMOTO, Tatsuya ODA, Nobuhiro OHKOHCHI, Masayuki NOGUCHI
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2016; 77(6): 1440. CrossRef
Biochemical remission by chemoradiotherapy in male mediastinal choriocarcinoma with diffuse lung metastasis: A case report
JING ZHANG, ZHI-JUN WANG, BIN YANG, YOU-YING WEI, LING YANG, YANG HU, YAN-PING HU
Oncology Letters.2016; 11(4): 2615. CrossRef
Primary gastric choriocarcinoma: A rare case
Vilma Florença Martins, Filipa Moreno, J. Ramón Vizcaíno, Jorge Santos
International Journal of Surgery Case Reports.2015; 14: 44. CrossRef
Resectable Primary Gastric Choriocarcinoma with Solitary Synchronous Liver Metastasis
Masafumi Tomita, Eisei Nishino, Tomoya Takami, Yu Oshima, Kotaro Hatano, Satoshi Wakama, Hayato Furue, Yasuhiro Matsuda, Naoki Kataoka, Tomoyuki Yamaguchi
The Japanese Journal of Gastroenterological Surgery.2015; 48(6): 488. CrossRef
Endometrioid adenocarcinoma with choriocarcinomatous differentiation: A case report and review of the literature
MITSUAKI ISHIDA, HIDETOSHI OKABE
Oncology Letters.2013; 6(3): 655. CrossRef
Gastric adenocarcinoma with choriocarcinomatous and hepatoid differentiation
Seong Wook Hwang, Sun Jae Lee, Po Eun Park, Mee Seon Kim, Han‐Ik Bae
Basic and Applied Pathology.2012; 5(1): 22. CrossRef
Pathological Complete Response and Two-year Disease-free Survival in a Primary Gastric Choriocarcinoma Patient with Advanced Liver Metastases Treated with Germ Cell Tumor-based Chemotherapy: A Case Report
Y. Waseda, Y. Komai, A. Yano, Y. Fujii, N. Noguchi, K. Kihara
Japanese Journal of Clinical Oncology.2012; 42(12): 1197. CrossRef
Gastric cancer with choriocarcinoma and yolk sac tumor components: Case report
Nobuo Satake, Motoya Chikakiyo, Toshiyuki Yagi, Yasuhiro Suzuki, Takanori Hirose
Pathology International.2011; 61(3): 156. CrossRef
A Coexistent Case of Primary Gastric Choriocarcinoma and Alpha Fetoprotein-producing Gastric Cancer which Caused Rapid Postoperative Progression
Naoya Sasaki, Yoshiharu Shirakata, Hisashi Shinohara, Kazumi Itoi, Atsuhiko Maki, Yoshifumi Mizuno, Rokuro Mimura, Koushou Takasu
The Japanese Journal of Gastroenterological Surgery.2011; 44(12): 1535. CrossRef

11,935 View
62 Download
18 Crossref

A Case of Acute Myelogenous Leukemia during Pregnancy: Jae Gyoon Lee, Sung Hyun Yang, Heung Tae Kim; J Korean Cancer Assoc. 1997;29(3):516-521.

Abstract PDF: The incidence of acute leukemia in pregnancy is rare. The treatment of acute leukemia during pregnancy is complicated and therapeutic options must be made with each individual patient. Complete remission can now be achieved in 60 to 70% of previously untreated adults with acute myelogenous leukemia (AML). Antileukemic chemotherapy can be administered safely during the second and third trimesters. Cytarabine (ara-C) and anthracycline has not been associated with birth defect. When a pregnant woman presents with acute leukemia, chemotherapy should be recommended as vigorously as in the non- pregnant woman. We reported a case of AML during pregnancy. The patient recieved induction chemotherapy with ara-C and idarubicin. The baby was delivered at 33 weeks of gestation and had transient neutropenia. The mother received consolidation chemotherapy after achievement of complete remission.

2,523 View
21 Download

Chemotherapy of Advanced Soft Tissue Sarcoma with Etoposide, Ifosfamide, and Cisplatin (VIP): Won Seog Kim, Kyung Hae Jung, Hyun Ah Kim, Sung Hyun Yang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(1):128-135.

Abstract PDF: PURPOSE
Soft tissue sarcomas are uncommon primary malignancies. So studies on the effective chemotherapy for soft tissue sarcomas are limited. We started this study to evaluate the effectiveness of VIP (etoposide, ifosfamide, cisplatin) combination chemotherapy for advanced soft tissue sarcomas.
MATERIALS AND METHODS
Thirty patients with recurrent or metastatic soft tissue sarcoma were treated with VIP combination chemotherapy between December 1989 and June 1996. Each patient was given etoposide 75 mg/m2, ifosfamide 1000 mg/m2, cisplatin 20 mg/m2 intravenously for five consecutive days every three weeks. Mesna (sodium-2-mercaptoethansulfonate) was given to avoid the urologic toxicity.
RESULTS
Twenty-eight of 30 patients were evaluable for response, and among the 28 evaluable patients, there were 9 partial response (32%). Duration of response in 9 responders ranged from 4.1 to 16.2 months (median 8.8 months). Overall survival ranged from 1.7 to 41.5 months (median 11 months) and survival was better for patients with partial response (median survival 14.8 months vs. 9.7 months with stable disease vs. 5.1 months with progressive disease p=0.0006). Nausea and vomiting was noted in more than 90% of cycles, but was markedly severe in only 4%. Leukopenia was noted in 60% of cycles, including 11% of cycles with counts <2,000/mm3. There was no treatment related death, but we had to stop chemotherapy in 2 patients due to leukopenia (1 patient) and neurotoxicity (1 patient).
CONCLUSION
Combination of etoposide, ifosfamide, and cisplatin was fairly active for advanced soft tissue sarcoma, with myelosuppresion and peripheral neuropathy being the most serious toxicities.

3,585 View
39 Download

Phase II trial of VP-16 plus cisplatin for advanced epithelial ovarian cancer: Young Iee Park, Tae Yoo Kim, Kyung Hae Jung, Sung Hyun Yang, Jung Ae Lee, Dae Suk Huh, Young Joo Bang, No Kyung Kim; J Korean Cancer Assoc. 1993;25(4):539-547.

Abstract PDF: No abstract available.

2,771 View
12 Download

Phase I study of subcutaneously administered recombinant human granulocyte-macrophage colony stimulating factor(GM-CSF) in patients with advanced malignancy: Jung Ae Lee, Hyun Ah Kim, Kyung Hoon Lee, Sung Hyun Yang, Dae Suk Huh, Young Joo Bang, Byung Kook Kim, No Kyung Kim; J Korean Cancer Assoc. 1993;25(4):520-530.

Abstract PDF: No abstract available.

2,699 View
13 Download

FAM versus etoposide, adriamycin, and cisplatin:a random assignment trial in advanced gastric cancer: Jung Ae Lee, Jung Soo Yoon, Sung Hyun Yang, Si Young Kim, Dae Suk Huh, Young Joo Bang, Kyung Sam Cho, No Kyung Kim; J Korean Cancer Assoc. 1993;25(4):461-467.

Abstract PDF: No abstract available.

2,483 View
13 Download

A case of carcinomatous polyarthritis: Suk In Lee, Woo Kyung Kim, Jae Suk Jun, Kyung Ran Baik, Sung Hyun Yang, Young Joo Bang, Young Ok Song; J Korean Cancer Assoc. 1993;25(2):307-314.

Abstract PDF: No abstract available.

2,653 View
20 Download

5-Fluorouracil , Leucovorin and Mitomycin C ( MLF ) Chemotherapy for Advanced Gastric Cancer : Results of A Phase 2 Trial: Sung Hyun Yang, Sung Rok Kim, Eun Soo Yang, Jong Cheol Ryu, Joon Hee Kim, Chul Soo Kim, Re Hwe Kim; J Korean Cancer Assoc. 1996;28(2):191-198.

Abstract PDF: The results of systemic chemotherapy for advanced stomach cancer are still disappointing despite of numerous studies which has been performed to develop better treatment regimens. Mitomycin C (MMC) is one of the most active agents against stomach cancer and leucovorin (LV) enhance cytotoxicity of 5-fluorouracil (5-FU). This clinical phase II trial was designed to evaluate the efficacy of combination chemotherapy with MMC and LV-modulated 5-FU (MLF). Thirty nine patients were entered into the trial. All patients had measurable lesion. The MLF reaimen consisted of 5-FU 375 mg/§³ IV days 1 through 5: LV 20 mg/§³ IV just before 5-FU infusion days 1 through 5; and MMC 9 mg/§³ IV day l (7mg/§³ from the 2nd cycle). Cycles were repeated every 4 weeks. There were 19 responses (48%) including 6 clinical complete responses. The median survival of all 39 patients was 40.4 weeks. There was minimal myelosuppression; grade 3-4 leucopenia or thrombocytopenia in 26% of cycles. Non-hematologic toxicities were also tolerable; grade 3 nausea or vomiting in 8% of patients. This phase II study showed that the MLF therepy is comparable in effect for advanced stomach cancer with minimal toxicities, deserving phase III study with other regimens.

3,729 View
29 Download

Search